Daily Ards Research Analysis
Three impactful studies span prevention, mechanism, and treatment in respiratory critical care. Antenatal main pulmonary artery Doppler and fetal lung biometry robustly predict early neonatal respiratory morbidity in fetal growth restriction, enabling precision perinatal planning. Mechanistically, IGF1R signaling emerges as a modulator of cytokine storm in acute lung injury, while an open-label RCT finds aerosolized dornase alfa does not improve COVID-19 ARDS, highlighting drug-delivery limitati
Summary
Three impactful studies span prevention, mechanism, and treatment in respiratory critical care. Antenatal main pulmonary artery Doppler and fetal lung biometry robustly predict early neonatal respiratory morbidity in fetal growth restriction, enabling precision perinatal planning. Mechanistically, IGF1R signaling emerges as a modulator of cytokine storm in acute lung injury, while an open-label RCT finds aerosolized dornase alfa does not improve COVID-19 ARDS, highlighting drug-delivery limitations.
Research Themes
- Perinatal respiratory risk stratification
- Inflammation and molecular targets in ARDS
- Therapeutic trials and drug delivery in ARDS
Selected Articles
1. Pulmonary Vascular Doppler and Fetal Lung Biometry as Predictors of Neonatal Respiratory Complications in Early- and Late-Onset Fetal Growth Restriction.
In a prospective cohort of 105 FGR and 108 control pregnancies, third-trimester MPA Doppler and 2D lung biometry independently predicted early neonatal respiratory morbidity. Cut-offs of PAT/ET <0.19, AT <50.5 ms, and lung volume <18.9 mL were informative, and combining PAT/ET with lung volume achieved 82% sensitivity and 72% specificity.
Impact: Provides actionable antenatal predictors with defined cut-offs to stratify respiratory risk in FGR, enabling timing of steroids and delivery planning.
Clinical Implications: Integrate MPA Doppler (PAT/ET, AT) and 2D lung volume into FGR surveillance to identify fetuses needing antenatal steroids, optimize delivery timing, and prepare neonatal respiratory support.
Key Findings
- CAPO occurred in 42.9% of FGR vs 10.2% of controls.
- Optimal prognostic cut-offs: PAT/ET <0.19, AT <50.5 ms, and lung volume <18.9 mL.
- PAT/ET <0.19, AT <50.5 ms, low lung volume, and preterm delivery independently predicted CAPO.
- Combining PAT/ET with lung volume yielded 82% sensitivity and 72% specificity.
Methodological Strengths
- Prospective cohort with contemporaneous controls and standardized ultrasound protocol
- Multivariable modeling identifying independent predictors with clinically usable cut-offs
- Composite clinical outcome reflecting real-world neonatal respiratory morbidity
Limitations
- Single tertiary-center setting may limit generalizability
- Composite outcome may mask differences between components
- No external validation cohort; operator dependence of 2D lung volume measurements
Future Directions: External validation across centers and integration into risk calculators; evaluate whether these markers guide steroid timing and delivery decisions to reduce respiratory morbidity.
OBJECTIVE: To determine the prognostic value of third trimester main pulmonary artery (MPA) Doppler indices, two dimensional (2D) lung volume, and thoracic circumference (TC) for composite adverse pulmonary outcome (CAPO) in pregnancies complicated by fetal growth restriction (FGR). METHODS: In this prospective cohort, 105 singleton FGR pregnancies (28 + 0 - 37 + 0 weeks) and 108 controls underwent standardized ultrasound at a tertiary center. MPA acceleration time (AT), ejection time (ET), and pulmonary AT to ET (PAT/ET) ratio were recorded. 2D lung volume and TC were calculated from axial thoracic sections. The CAPO comprised ≥ 1 of: 5-min Apgar < 7, respiratory distress syndrome (RDS), continuous positive airway pressure (CPAP), mechanical ventilation, or neonatal intensive care unit (NICU) admission for respiratory compromise. RESULTS: Compared with controls, FGR fetuses had smaller lung volume and TC, higher MPA pulsatility/resistance indices, and lower PAT/ET. CAPO occurred in 42.9% of FGR versus 10.2% of controls. Optimal cut-offs were AT < 50.5 ms, PAT/ET < 0.19, and lung volume < 18.9 mL. In multivariable analysis, PAT/ET < 0.19, AT < 50.5 ms, lung volume < 18.9 mL and preterm delivery independently predicted CAPO. Combining PAT/ET and lung volume increased sensitivity to 82% with 72% specificity. CONCLUSIONS: Reduced lung volume and aberrant MPA Doppler profiles identify growth restricted fetuses at heightened risk of early neonatal respiratory morbidity. Integrating these pulmonary markers into FGR surveillance may enhance antenatal risk assessment, optimize steroid and delivery timing, and improve neonatal respiratory outcomes.
2. IGF1R deficiency mitigates acute lung injury by promoting anti-inflammatory transcriptional profiles.
Cross-species transcriptomic analyses and mouse experimentation show that IGF1R is broadly expressed in lung cells and that Igf1r deficiency reverses bleomycin-induced inflammatory programs. The work links IGF1R signaling to modulation of cytokine storm, mitochondrial and metabolic pathways, and epigenetic marks, nominating IGF1R as a therapeutic target in ALI/ARDS.
Impact: Identifies a plausible and druggable pathway that reshapes inflammatory and epigenetic responses in lung injury with multi-omic, in vivo and in vitro support.
Clinical Implications: Supports exploration of IGF1R-targeted therapies or pathway modulators to mitigate hyperinflammation in ALI/ARDS, with attention to selectivity and metabolic safety.
Key Findings
- IGF1R is broadly expressed across multiple pulmonary cell types in human and mouse lungs.
- Igf1r deficiency reverses a large fraction of bleomycin-induced inflammatory transcriptomic changes, including cytokine-storm genes.
- Pathways related to DNA damage, mitochondrial homeostasis, metabolic reprogramming, and epigenetic regulation are modulated.
- Igf1r-deficient MEFs show decreased respiration/glycolysis and protection from nuclear damage; lungs exhibit increased global DNA methylation post-injury.
Methodological Strengths
- Integrated single-cell and bulk RNA sequencing across species with functional enrichment analyses
- Convergent in vivo mouse model, ex vivo tissue assays, and in vitro MEF functional validation
- Multi-dimensional readouts including protein, DNA damage, mitochondrial metrics, and epigenetic marks
Limitations
- Bleomycin-induced injury model may not recapitulate all ARDS etiologies
- Global genetic deficiency may not mimic pharmacologic inhibition and could have off-target systemic effects
- Limited temporal resolution (e.g., 3-day time point for bulk RNA-seq) and no interventional clinical data
Future Directions: Test selective IGF1R inhibitors or pathway modulators in multiple ALI/ARDS models and evaluate safety/efficacy; map cell-type specific signaling and therapeutic windows.
BACKGROUND: Acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and COVID-19 are characterized by hyperinflammation, commonly referred to as "cytokine storm". The insulin-like growth factor (IGF) pathway, particularly the type 1 receptor (IGF1R), plays a critical role in lung homeostasis and has been implicated in the pathogenesis of pulmonary inflammatory diseases. In mice, widespread Igf1r deficiency attenuates lung inflammation and alveolar damage in bleomycin (BLM)-induced ALI. METHODS: We analyzed single-cell RNA sequencing datasets from lung tissue of COVID-19 cases and control donors as well as mouse lungs to determine Igf1r and IGF family expression across pulmonary cell types. Furthermore, we conducted bulk RNA sequencing on lungs from Igf1r-deficient mice three days after BLM or saline instillation, followed by differential expression and functional enrichment analyses. Findings were further tested through protein detection, assessment of DNA damage and methylation in lung tissues, and functional assays using Igf1r-deficient primary mouse embryonic fibroblasts (MEFs). RESULTS: IGF1R was broadly expressed across multiple cell types in both human and mouse lungs under normal and pathological conditions. Other IGF family members showed cell-type-specific expression, which was modulated by lung injury. Transcriptomic profiling revealed differentially expressed genes between BLM-challenged and control mouse lungs, detecting biological processes and signaling pathways involved in ALI pathobiology. Igf1r deficiency in BLM-challenged mice reversed a large fraction of the transcriptional changes triggered by BLM, including "cytokine storm"-related gene expression. Functional enrichment analysis additionally revealed significant modulation of pathways related to DNA damage, metabolic reprogramming, mitochondrial homeostasis, and epigenetic regulation. In vitro, Igf1r-deficient MEFs exhibited decreased mitochondrial respiration and glycolysis, protection against BLM-induced nuclear damage and mitochondrial accumulation, and decreased histone H3 acetylation. Moreover, Igf1r-deficient mouse lungs displayed increased global DNA methylation following BLM challenge. CONCLUSIONS: IGF1R is a key modulator of the inflammatory and molecular response to ALI pathogenesis. IGF1R deficiency dampens the "cytokine storm", modifies transcriptional and epigenetic profiles and promotes protective cellular responses. These findings highlight IGF1R signaling as a potential therapeutic target in ARDS and related lung injuries.
3. Multicenter randomized trial assessing efficacy and safety of aerosolized dornase Alfa in COVID-19 ARDS.
In a multicenter, open-label RCT of intubated COVID-19 ARDS (n=77), aerosolized dornase alfa did not improve ARDS severity at Day 7 or key clinical outcomes versus standard care. Biomarker analyses suggest inadequate in vivo DNAse activity with aerosol delivery, indicating a drug-delivery rather than target-failure issue.
Impact: Provides randomized evidence against aerosolized dornase alfa in COVID-19 ARDS and clarifies that bioavailability limits likely explain the lack of effect, refining future trial design.
Clinical Implications: Routine use of aerosolized dornase alfa in invasively ventilated COVID-19 ARDS is not supported. Alternative delivery strategies (e.g., direct instillation or optimized nebulization) and biomarker-enriched designs should be considered.
Key Findings
- Day-7 ARDS severity improvement: 18% with dornase alfa vs 29% with standard care (adjusted OR 0.33; 95% CI 0.09–1.14; p=0.11).
- No significant differences in 28-day mortality, ventilator-free days, or ICU-free days.
- Similar safety profiles between arms (adverse events 38.5% vs 31.6%).
- Biological sampling showed no meaningful increase in DNAse activity or reduction in NET markers, implicating aerosol delivery bioavailability limitations.
Methodological Strengths
- Multicenter randomized controlled design with trial registration (NCT04355364)
- Integrated biological analyses of NETs and drug activity to interrogate mechanism and delivery
- Pragmatic comparison against standard-of-care in ventilated ARDS patients
Limitations
- Open-label design and modest sample size may limit power and introduce bias
- Aerosol delivery through ventilator circuits may have impeded effective airway deposition
- Heterogeneity in SOC and evolving COVID-19 variants could confound effects
Future Directions: Evaluate alternative delivery (e.g., intratracheal) and patient enrichment (high NET burden) in blinded RCTs; optimize aerosol devices for ICU circuits and measure airway deposition in vivo.
Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 infection is associated with high mortality rates and respiratory compromise in which excessive neutrophil extracellular trap (NET) production may amplify alveolar inflammation and injury. Dornase alfa, a recombinant DNAse 1, has been proposed to attenuate these effects by degrading extracellular DNA and enhancing alveolar clearance of NETs. In this multicenter, open-label, randomized in two parallel arms (1:1) controlled trial, intubated COVID-19 ARDS patients received either standard-of-care (SOC) alone or SOC plus aerosolized dornase alfa (2500 IU twice daily for 7 days). The primary endpoint was the proportion of patients with ARDS severity improvement at Day 7, defined by at least one-grade improvement on the Berlin criteria scale. Secondary outcomes included 28-day mortality, ventilator-free days, ICU-free days, and changes in key ventilatory parameters. Biological samples were analyzed to assess NET related markers, DNAse drug activity and indicate possible bioavailability issues associated with aerosolization of dornase alfa. Seventy-seven patients were enrolled (dornase alfa group, n = 39; SOC group, n = 38). At Day 7, ARDS severity improved in 18% of patients receiving dornase alfa compared with 29% in the SOC group (adjusted OR: 0.33; 95% CI 0.09-1.14; p = 0.11). Secondary endpoints, including 28-day mortality, ventilator-free days, and ICU-free days, showed no significant differences between groups. Adverse events occurred in 38.5% of patients in the dornase alfa arm versus 31.6% in the SOC arm, indicating comparable safety profiles. Despite early increases in NET plasmatic levels observed in both groups and successful ex vivo NET degradation, aerosolized dornase alfa failed to significantly enhance DNAse activity or reduce NET-related markers in patients' plasma and mucus, suggesting potential bioavailability limitations with this delivery method. In patients with COVID-19-related ARDS, dornase alfa did neither significantly reduce ARDS severity nor improve clinical outcomes over SOC. Although well tolerated, analysis of biological samples suggests that aerosol administration may have compromised drug bioavailability. Further trials are needed to determine whether specific patient subgroups could benefit more from dornase alfa or if alternative drug delivery methods might enhance treatment efficacy. ClinicalTrials.gov, NCT04355364. Registered on 21/04/2020.